Silapaswan Andrew, Krakower Douglas, Mayer Kenneth H
Fenway Health, The Fenway Institute, 1340 Boylston St., Boston, MA, 02215, USA.
New York Medical College, Valhalla, NY, USA.
J Gen Intern Med. 2017 Feb;32(2):192-198. doi: 10.1007/s11606-016-3899-4. Epub 2016 Oct 19.
Since FDA approval of HIV pre-exposure prophylaxis (PrEP) for HIV prevention, attention has been focused on PrEP implementation. The CDC estimates that 1.2 million U.S. adults might benefit from PrEP, but only a minority are using PrEP, so there is a significant unmet need to increase access for those at risk for HIV. Given the large numbers of individuals who have indications for PrEP, there are not enough practicing specialists to meet the growing need for providers trained in providing PrEP. Moreover, since PrEP is a preventive intervention for otherwise healthy individuals, primary care providers (PCPs) should be primary prescribers of PrEP. There are important clinical considerations that providers should take into account when planning to prescribe PrEP, which are highlighted in the clinical case discussed. A growing body of research also suggests that some providers may be cautious about prescribing PrEP because of concerns regarding its "real-world" effectiveness, anticipated unintended consequences associated with its use, and ambiguity as to who should prescribe it. This review summarizes findings from studies that have assessed prescriber behavior regarding provision of PrEP, and offers recommendations on how to optimize PrEP implementation in primary care settings. Development and dissemination of educational interventions for PCPs and potential PrEP users are needed, including improved methods to assist clinicians in identifying appropriate PrEP candidates, and programs to promote medication adherence and access to social and behavioral health services. PCPs are well-positioned to prescribe PrEP and coordinate health-related services to improve the sexual health of their patients, but tailored educational programs are needed.
自美国食品药品监督管理局(FDA)批准将艾滋病病毒暴露前预防(PrEP)用于艾滋病预防以来,人们的注意力一直集中在PrEP的实施上。美国疾病控制与预防中心(CDC)估计,120万美国成年人可能会从PrEP中受益,但只有少数人在使用PrEP,因此对于增加艾滋病病毒高危人群的获取途径仍有巨大的未满足需求。鉴于有大量个体有PrEP的适应证,但没有足够多的执业专科医生来满足对接受PrEP培训的医疗服务提供者日益增长的需求。此外,由于PrEP是针对原本健康个体的预防性干预措施,初级保健提供者(PCP)应成为PrEP的主要开处方者。在计划开处方PrEP时,医疗服务提供者应考虑一些重要的临床因素,这些因素在讨论的临床病例中得到了强调。越来越多的研究还表明,一些医疗服务提供者可能对开处方PrEP持谨慎态度,原因包括对其“实际效果”的担忧、与其使用相关的预期意外后果,以及关于应由谁开处方的不明确性。本综述总结了评估医疗服务提供者在提供PrEP方面行为的研究结果,并就如何在初级保健环境中优化PrEP的实施提出了建议。需要为初级保健提供者和潜在的PrEP使用者开发和传播教育干预措施,包括改进协助临床医生识别合适PrEP候选者的方法,以及促进药物依从性和获取社会及行为健康服务的项目。初级保健提供者在开处方PrEP和协调与健康相关服务以改善患者性健康方面具有有利地位,但需要量身定制的教育项目。
AIDS Patient Care STDS. 2020-2-28
Int J Environ Res Public Health. 2024-1-31
Singapore Med J. 2023-10
Curr Opin HIV AIDS. 2016-5
Clin Infect Dis. 2016-5-1
N Engl J Med. 2015-12-1
Curr Opin HIV AIDS. 2016-1